Online inquiry

IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1825MR)

This product GTTS-WQ1825MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CFD gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317335.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1675
UniProt ID P00746
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1825MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10056MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ15679MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ5854MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ231MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ3205MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ7872MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ14827MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-75
GTTS-WQ11516MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MFGR1877S
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW